GKT137831: Selective Nox1/Nox4 Inhibitor for Oxidative Stress Research

Executive Summary: GKT137831 is a highly selective dual inhibitor of NADPH oxidases Nox1 and Nox4, exhibiting Ki values of 140 nM and 110 nM, respectively, under in vitro conditions (APExBIO product page). It attenuates reactive oxygen species (ROS) production, modulating key redox-sensitive signaling pathways, including Akt/mTOR and NF-κB, as demonstrated in human pulmonary artery cell models (Yang et al. 2025). Oral administration in mouse models at 30–60 mg/kg/day reduces pulmonary vascular remodeling, right ventricular hypertrophy, liver fibrosis, and diabetes-accelerated atherosclerosis. GKT137831 is soluble at ≥39.5 mg/mL in DMSO and is recommended for storage at -20°C. It is distributed by APExBIO as catalog B4763 for oxidative stress research applications.

Biological Rationale

Reactive oxygen species (ROS) are central mediators of cellular signaling and oxidative damage in multiple pathologies, including fibrosis, vascular remodeling, and atherosclerosis (Yang et al. 2025). NADPH oxidases Nox1 and Nox4 are major sources of non-mitochondrial ROS. Their dysregulation increases hydrogen peroxide (H₂O₂) and other ROS, promoting pathological signaling cascades. Selective inhibition of Nox1/Nox4 is a validated strategy to reduce sustained oxidative stress without broadly affecting redox homeostasis (see related dossier). GKT137831 enables interrogation of Nox1/Nox4-specific ROS contributions distinct from other oxidase isoforms. This supports mechanistic and translational studies in inflammation, fibrosis, and redox-driven vascular pathologies.

Mechanism of Action of GKT137831

GKT137831 directly inhibits the enzymatic activity of NADPH oxidases Nox1 and Nox4, with inhibitory constants (Ki) of 140 nM (Nox1) and 110 nM (Nox4) in standard biochemical assays (APExBIO). By blocking substrate turnover, it reduces ROS generation at the point of origin. This leads to attenuation of downstream Akt/mTOR and NF-κB signaling pathways, which are activated by ROS in inflammatory and fibrotic contexts (Yang et al. 2025, Fig. 3). In cell models, GKT137831 reduces hypoxia-induced H₂O₂ release and inhibits proliferation of human pulmonary artery endothelial and smooth muscle cells. It also modulates expression of TGF-β1, a pro-fibrotic cytokine, and PPARγ, a regulator of metabolic and inflammatory responses. These effects are concentration- and time-dependent, with typical use at 0.1–20 μM for 24 hours in vitro. The compound does not inhibit other NADPH oxidase isoforms (e.g., Nox2) at relevant concentrations (see comparative article).

Evidence & Benchmarks

• GKT137831 inhibits Nox1 (Ki = 140 nM) and Nox4 (Ki = 110 nM) in vitro, with no significant effect on Nox2 at up to 1 μM (APExBIO).
• Reduces hypoxia-induced H₂O₂ release in human pulmonary artery endothelial cells (HPAECs) after 24 h at 1–10 μM (Yang et al. 2025, Extended Data Fig. 2).
• Suppresses proliferation of HPAECs and human pulmonary artery smooth muscle cells (HPASMCs) in response to hypoxia at 5–10 μM (Yang et al. 2025).
• Downregulates TGF-β1 and upregulates PPARγ expression in vitro, consistent with anti-fibrotic and anti-inflammatory effects (see advanced review).
• Oral dosing at 30–60 mg/kg/day attenuates pulmonary vascular remodeling, right ventricular hypertrophy, and liver fibrosis in mouse models of chronic hypoxia and CCl₄-induced injury (Yang et al. 2025, Table 1).
• Mitigates diabetes-accelerated atherosclerosis in ApoE^-/- mice, reducing plaque burden and vascular inflammation at 30 mg/kg/day for 4 weeks (APExBIO).
• Demonstrates excellent solubility in DMSO (≥39.5 mg/mL), moderate solubility in ethanol (≥2.96 mg/mL), but is insoluble in water (APExBIO).
• Has been evaluated in clinical studies for safety and efficacy in human subjects with fibrotic disorders (Yang et al. 2025, Discussion).

Applications, Limits & Misconceptions

GKT137831 is primarily used in research on oxidative stress, fibrosis, vascular remodeling, and metabolic vascular disease models. It is suitable for in vitro and in vivo studies where selective inhibition of Nox1/Nox4 is required. Researchers should note that it does not broadly suppress all ROS sources or inhibit other NADPH oxidase isoforms outside Nox1/Nox4. Its translational value is highlighted in fibrosis and atherosclerosis models, but its efficacy may be context-dependent, as not all ROS-driven pathologies are Nox1/Nox4 dependent (review clarifies strategic scope).

Common Pitfalls or Misconceptions

• GKT137831 does not inhibit mitochondrial ROS production; its activity is restricted to NADPH oxidase-driven ROS (APExBIO).
• It is ineffective against ROS generated by Nox2, Nox3, or other oxidases at recommended experimental concentrations.
• Inactive in cell-free ROS assays lacking Nox1/Nox4 enzyme sources.
• Solubility in water is negligible; improper solvent use (e.g., water) leads to precipitation and loss of activity.
• Long-term storage of solutions (>1 week) is not recommended due to compound degradation at room temperature.

Workflow Integration & Parameters

For in vitro assays, dissolve GKT137831 in DMSO to achieve a stock concentration ≥39.5 mg/mL. Dilute to final concentrations of 0.1–20 μM in culture medium, ensuring DMSO content does not exceed 0.1% (v/v). Typical incubation periods are 24 hours, but time courses may be adjusted based on cell type and endpoint. For in vivo studies, administer GKT137831 orally at 30–60 mg/kg/day, either by gavage or in chow, for up to 8 weeks. Store powder at -20°C; avoid repeated freeze–thaw cycles. For benchmarking, include positive and negative controls (e.g., Nox2-specific inhibitors, ROS scavengers) to confirm selectivity. Refer to the B4763 kit specification for detailed handling and usage guidance.

This article extends the discussion in 'GKT137831: Dual Nox1/Nox4 Inhibitor for Advanced Oxidative Stress Investigation' by providing a more granular breakdown of experimental parameters and pitfalls, and clarifies selectivity boundaries discussed in 'GKT137831: Selective Nox1/Nox4 Inhibitor for Oxidative Stress Research'.

Conclusion & Outlook

GKT137831 has set a benchmark for selective, dual inhibition of Nox1/Nox4 in oxidative stress research. Its utility spans mechanistic studies, translational models of fibrosis and vascular remodeling, and workflow troubleshooting for redox biology. APExBIO's distribution of GKT137831 as B4763 provides researchers with a validated, high-purity reagent for advanced applications. Ongoing clinical and preclinical studies continue to define its therapeutic potential in human disease models. For comprehensive protocols and product data, consult the APExBIO GKT137831 page.